JINYU(SH:600201)2015-03-18 16:00Financial Performance - The company's operating revenue for 2014 reached ¥1,062,932,025.01, representing a 58.32% increase compared to ¥671,382,978.89 in 2013[24] - Net profit attributable to shareholders was ¥404,321,363.18, up 61.16% from ¥250,883,061.53 in the previous year[24] - The basic earnings per share increased to ¥1.44, a 61.80% rise from ¥0.89 in 2013[25] - The total assets of the company at the end of 2014 were ¥2,097,994,791.53, reflecting a 22.57% increase from ¥1,711,664,428.69 in 2013[24] - The net assets attributable to shareholders increased by 27.37% to ¥1,632,654,041.63 from ¥1,281,791,857.85 in 2013[24] - The cash flow from operating activities was ¥585,186,590.74, a decrease of 9.88% compared to ¥649,339,640.78 in 2013[24] - The company achieved a sales revenue of 1.063 billion RMB, a growth of 58.3% compared to the previous year, and a net profit of 404 million RMB, increasing by 61%[31] - The earnings per share (EPS) reached 1.44 RMB, reflecting a 61.8% increase year-over-year[31] Dividends and Profit Distribution - The company plans to distribute a cash dividend of ¥3 per 10 shares, totaling ¥85,756,479.00[3] - The company distributed cash dividends of 2.80 yuan per 10 shares, totaling 78,628,180.40 yuan, based on a total share capital of 280,814,930 shares as of December 31, 2013[91] - The company has a cash dividend policy that requires at least 30% of the average distributable profit over the last three years to be distributed in cash[86] - The company achieved a net profit of RMB 404,321,363.18 in 2014, with a cash dividend payout ratio of 21.21%[94] Research and Development - The company’s R&D expenditure totaled ¥27,946,823.51, accounting for 2.63% of operating revenue and 1.71% of net assets[50] - The company established a national engineering laboratory for veterinary vaccines, enhancing its R&D capabilities and competitive edge in the industry[61] - The company is focusing on technological advancements and innovation to maintain competitive advantage in the industry[132] Market and Sales Performance - The government procurement revenue from vaccines increased by 37%, while direct sales of vaccines surged by 108%[38] - The company’s new trivalent vaccine for foot-and-mouth disease gained significant market share and became a new source of profit growth[40] - Domestic revenue increased by 58.58% to ¥1,057,206,025.01, while foreign revenue was ¥5,726,000.00[58] - The company established a dedicated marketing team for large-scale farms, leading to a significant increase in sales orders[39] Capital and Investments - The company completed the issuance of restricted stock to 93 individuals, granting a total of 5.04 million shares, enhancing the alignment of interests between shareholders and the management team[33] - The company plans to issue 27,245,070 shares to raise ¥799,097,903.10 for working capital, which has been approved by the shareholders and is currently under review by the China Securities Regulatory Commission[52] - The company initiated a non-public stock issuance to supplement working capital, which was accepted by the China Securities Regulatory Commission in November 2014[33] Environmental and Social Responsibility - The company has maintained a 95% operational rate for its environmental protection facilities, ensuring compliance with national emission standards[94] - The company has established a comprehensive environmental management system to ensure sustainable development[93] - The company organized a blood donation event, with employees donating a total of 12,200 milliliters of blood in January 2014[92] Governance and Compliance - The company has established a performance evaluation mechanism for senior management, linking their annual salary to responsibilities and contributions[161] - The company has strictly adhered to the regulations regarding insider information, with no incidents of leakage or insider trading reported by the end of the reporting period[151] - The company’s governance structure aligns with the requirements of the Company Law and the China Securities Regulatory Commission[151] Shareholding Structure - The total number of shareholders at the end of the reporting period was 11,594, an increase from 9,393 prior to the report[117] - The largest shareholder, Inner Mongolia Agricultural and Animal Husbandry Pharmaceutical Co., Ltd., held 33,600,000 shares, representing 11.75% of the total shares[119] - The company does not have a controlling shareholder, indicating a dispersed shareholding structure[123] Financial Position - Total liabilities increased to CNY 467,500,864.84 from CNY 429,828,363.61, representing a growth of approximately 8% year-over-year[178] - Total owner's equity rose to CNY 1,630,493,926.69 from CNY 1,281,836,065.08, marking an increase of about 27%[179] - The company reported a total asset value of CNY 2,097,994,791.53, compared to CNY 1,711,664,428.69, reflecting a growth of about 22.6%[179]